Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIROCCO: Octreotide LAR Dose Optimization in Carcinoid Syndrome
NCT04140409Phase 4Terminated
- Start
- Feb 2016
- Primary completion
- Jun 2019
- Modality
- Peptides
01
Overview
A Phase 4 trial of Octreotide long-acting injection in Carcinoid Syndrome (CS). Started Feb 2016; status: terminated.
02
Drugs
Octreotide long-acting injection
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT04140409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04140409.